Medtronic — Q1 FY27 Earnings Summary

Financial Performance

• Worldwide revenue reached $9.756 billion, a 13.7% increase as reported and 13.7% organic, roughly 200 basis points above the guidance midpoint.
• GAAP diluted EPS was $1.14, a 40.7% increase year-over-year; non-GAAP diluted EPS was $1.45, a 15.1% increase year-over-year.
• GAAP operating profit was $1.764 billion (18.1% margin), up 22.1% and 120 basis points respectively; non-GAAP operating profit was $2.316 billion (23.7% margin), up 14.9% and 10 basis points respectively.
• GAAP net income was $1.470 billion, up 41.4% year-over-year; non-GAAP net income was $1.860 billion, up 14.4% year-over-year.
• Free cash flow was $1.290 billion, compared to $584 million in the prior year quarter.
• Net cash provided by operating activities was $1.793 billion, up from $1.088 billion in the prior year.
• Cash paid for dividends to shareholders was $921 million; repurchases of ordinary shares totaled $267 million.
• The quarter included an extra fiscal week which benefited organic growth by approximately $570 million.
• Foreign exchange provided a benefit of $57 million on remaining net sales.

Guidance and Future Outlook

• Raised FY27 organic revenue growth guidance by 50 basis points to a range of 7.25% to 7.75% (prior: 6.75% to 7.25%).
• Raised FY27 diluted non-GAAP EPS guidance to a range of $5.94 to $6.00 (prior: $5.90 to $6.00).
• New guidance includes an estimated neutral to 1% accretive impact from foreign currency exchange based on recent rates.
• Management cites strong operating performance and disciplined financial management as drivers for the raised guidance.

Business Segments and Product Lines

• Cardiovascular Portfolio revenue grew 18.9% organic to $3.927 billion, led by 29.1% organic growth in Electrophysiology Therapies and 11.0% organic growth in Peripheral Vascular Health.
• Neuroscience Portfolio revenue grew 9.3% organic to $2.678 billion, driven by 12.9% organic growth in Cranial & Spinal Technologies and 15% growth in Pelvic Health (Altaviva contribution).
• Medical Surgical Portfolio revenue grew 10.2% organic to $2.279 billion, with 14.2% organic growth in Acute & Monitoring and 9.0% organic growth in Surgical & Endoscopy.
• Diabetes business revenue grew 14.9% organic to $843 million.
• Completed acquisitions of Scientia Vascular (closed June 12) and SPR Therapeutics, Inc. (closed July 16).
• Announced expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for ventricular arrhythmias.
• Announced a strategic partnership with Cornerstone Robotics to expand global access to robotic-assisted surgery.
• Received FDA clearance for Touch Surgery™ Aide next generation computing platform.
• Made a strategic investment in Pi-Cardia, a pioneer in leaflet modification technology.

Market and Competitive Landscape

• Broad-based portfolio performance across largest franchises and new growth platforms supports the long-term growth trajectory.
• The company operates in the global healthcare technology sector, treating 70 health conditions across more than 150 countries.

Risks and Challenges

• Forward-looking statements are subject to risks including competitive factors, difficulties in product development and marketing, government regulation, geopolitical conflicts, changing global trade policies, and material acquisition/divestiture transactions.
• The separation of the Diabetes business is ongoing and may involve various capital markets transactions (spin-off, split-off, offering) with a final structure not yet decided.
• Non-GAAP financial measures exclude certain charges or gains that may or may not recur, and management notes these should be considered supplemental to GAAP measures.

Management Commentary and Tone

• CEO Geoff Martha stated the company is "off to a strong start" with confidence derived from the breadth of performance and increasing contributions from newer growth platforms.
• CFO Thierry Piéton highlighted that strong operating performance and disciplined financial management drove results ahead of expectations.
• Management expressed confidence in the portfolio and pipeline to serve more patients and deliver durable growth.

Other Key Points

• The Diabetes business results presented may not correspond to financial statement information presented by MiniMed Group, Inc. due to different preparation bases (carve-out vs. standalone).
• The company has 95,000+ employees globally.
• Restructuring charges, net were $72 million in the current quarter versus $45 million in the prior year.
• Acquisition and divestiture-related items were $50 million in the current quarter versus $58 million in the prior year.
• A gain on minority investments of $64 million was recorded in the current quarter, compared to a loss of $113 million in the prior year.
• Adjustments to Italian payback accruals related to a June 30, 2025 Legislative Decree impacted prior year results.